Liquidia Corp (LQDA): R&D Expense
$39.28M
Year ended 2025-12-31
$56.04M
Trailing 12 months to 2026-06-30
+26.4%
3-year compound annual growth
+4.0%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $39.28M | -17.9% | 2026-03-05, From 2025-01-01 |
| 2024-12-31 | $47.84M | +10.6% | 2026-03-05, From 2024-01-01 |
| 2023-12-31 | $43.24M | +122.5% | 2026-03-05, From 2023-01-01 |
| 2022-12-31 | $19.43M | -5.3% | 2024-03-13, From 2022-01-01 |
| 2021-12-31 | $20.52M | -36.3% | 2023-03-20, From 2021-01-01 |
| 2020-12-31 | $32.22M | -20.4% | 2022-03-17, From 2020-01-01 |
| 2019-12-31 | $40.49M | n/a | 2021-03-25, From 2019-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Liquidia Corp (LQDA) | 2025-12-31 | $39.28M | -17.9% |
| Heron Therapeutics, Inc. (HRTX) | 2025-12-31 | $12.43M | -25.5% |
| Macrogenics Inc (MGNX) | 2025-12-31 | $147.17M | -16.9% |
| Elite Pharmaceuticals Inc (ELTP) | 2026-03-31 | $5.74M | -27.9% |
| Karyopharm Therapeutics Inc. (KPTI) | 2025-12-31 | $125.62M | -12.3% |
| Syndax Pharmaceuticals Inc (SNDX) | 2025-12-31 | $258.78M | +7.1% |
| Phathom Pharmaceuticals, Inc. (PHAT) | 2025-12-31 | $32.78M | -3.8% |
| Cryoport, Inc. (CYRX) | 2025-12-31 | $17.04M | -3.8% |
| Lifevantage Corp (LFVN) | 2026-06-30 | $1.00M | -28.6% |
Compare LQDA, HRTX, MGNX, ELTP side by side · Screen every company in Pharmaceutical Preparations ↗